{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T23:53:38Z","timestamp":1768175618574,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12149-025-02103-x","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T13:54:13Z","timestamp":1757512453000},"page":"50-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interobserver and intraobserver agreement for equivocal lesions in Ga-68 PSMA PET\/CT according to PSMA-RADS 2.0 criteria"],"prefix":"10.1007","volume":"40","author":[{"given":"Khanim","family":"Niftaliyeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-9781","authenticated-orcid":false,"given":"Selin","family":"Kesim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuh","family":"Filizoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep Ceren","family":"Balaban Genc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salih","family":"Ozguven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feyza","family":"Cagliyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tunc","family":"Ones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuat","family":"Dede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halil Turgut","family":"Turoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanju Yusuf","family":"Erdil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"2103_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363.","journal-title":"Eur Urol"},{"key":"2103_CR2","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2103_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","volume":"38","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics. 2018;38:200\u201317.","journal-title":"Radiographics"},{"key":"2103_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed mitnm classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59:469\u201378.","journal-title":"J Nucl Med"},{"key":"2103_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405\u201312.","journal-title":"Eur Urol"},{"key":"2103_CR6","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00259-017-3725-1","volume":"44","author":"S Fanti","year":"2017","unstructured":"Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, et al. Development of standardized image interpretation for 68Ga-PSMA PET\/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. 2017;44:1622\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2103_CR7","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2103_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2967\/jnumed.117.195255","volume":"59","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J Nucl Med. 2018;59:479\u201385.","journal-title":"J Nucl Med"},{"key":"2103_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","volume":"84","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T, et al. Prostate-specific membrane antigen reporting and data system version 2.0. Eur Urol. 2023;84:491\u2013502.","journal-title":"Eur Urol"},{"key":"2103_CR10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00330-023-10083-7","volume":"34","author":"F Grawe","year":"2024","unstructured":"Grawe F, Blom F, Winkelmann M, Burgard C, Schmid-Tannwald C, Unterrainer LM, et al. Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET\/CT scans in prostate cancer patients. Eur Radiol. 2024;34:1157\u201366.","journal-title":"Eur Radiol"},{"key":"2103_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13550-020-0596-4","volume":"10","author":"C Derwael","year":"2020","unstructured":"Derwael C, Lavergne O, Lovinfosse P, Nechifor V, Salv\u00e9 M, Waltregny D, et al. Interobserver agreement of [68Ga]Ga-PSMA-11 PET\/CT images interpretation in men with newly diagnosed prostate cancer. EJNMMI Res. 2020;10:15.","journal-title":"EJNMMI Res"},{"key":"2103_CR12","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/jnumed.118.217588","volume":"59","author":"RA Werner","year":"2018","unstructured":"Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, et al. Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET\/CT imaging. J Nucl Med. 2018;59:1857\u201364.","journal-title":"J Nucl Med"},{"key":"2103_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/RLU.0000000000004524","volume":"48","author":"RA Bundschuh","year":"2023","unstructured":"Bundschuh RA, L\u00fctje S, Bundschuh L, Lapa C, Higuchi T, Hartrampf PE, et al. High interobserver agreement on PSMA PET\/CT even in the absence of clinical data. Clin Nucl Med. 2023;48:207\u201312.","journal-title":"Clin Nucl Med"},{"key":"2103_CR14","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/diagnostics14121291","volume":"14","author":"G Masselli","year":"2024","unstructured":"Masselli G, Sollaku S, De Angelis C, Polettini E, Gualdi G, Casciani E. 68Ga-PSMA PET\/CT in recurrent prostate cancer after radical prostatectomy using PSMA-RADS version 2.0. Diagnostics. 2024;14:1291.","journal-title":"Diagnostics"},{"key":"2103_CR15","doi-asserted-by":"publisher","first-page":"500047","DOI":"10.1016\/j.remnie.2024.500047","volume":"43","author":"M Guerra-G\u00f3mez","year":"2024","unstructured":"Guerra-G\u00f3mez M, Rodr\u00edguez-Pajuelo A, Brero-S\u00e1nchez L, Cuenca-Cuenca JI, \u00c1lvarez-P\u00e9rez RM, Freire-Mac\u00edas JM, et al. Interobserver and intraobserver agreement in PET\/CT with [18F]DCFPyL according to TNM molecular and PSMA-RADS 2.0 criteria. Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition). 2024;43:500047.","journal-title":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"},{"key":"2103_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MNM.0000000000001485","volume":"43","author":"NP Karahan \u015een","year":"2022","unstructured":"Karahan \u015een NP, Aksu A, Bozkurt O, Tuna EB, \u00c7apa Kaya G. Interreader agreement in evaluation of 68Ga-PSMA PET\/CT at the time of initial staging: comparison of the three evaluation criteria in the pretreatment risk groups. Nucl Med Commun. 2022;43:86\u201391.","journal-title":"Nucl Med Commun"},{"key":"2103_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/MNM.0000000000001219","volume":"41","author":"E Demirci","year":"2020","unstructured":"Demirci E, Akyel R, Caner B, Alan-Sel\u00e7uk N, G\u00fcven-Me\u015fe \u015e, Ocak M, et al. Interobserver and intraobserver agreement on prostate-specific membrane antigen PET\/CT images according to the miTNM and PSMA-RADS criteria. Nucl Med Commun. 2020;41:759\u201367.","journal-title":"Nucl Med Commun"},{"key":"2103_CR18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.2967\/jnumed.124.267899","volume":"65","author":"IC Mainta","year":"2024","unstructured":"Mainta IC, Neroladaki A, Wolf NB, Benamran D, Boudabbous S, Zilli T, et al. [68Ga]Ga-PSMA-11 PET and prostate cancer bone metastases: diagnostic performance of available standardized criteria. J Nucl Med. 2024;65:1376\u201382.","journal-title":"J Nucl Med"},{"key":"2103_CR19","doi-asserted-by":"publisher","first-page":"1368093","DOI":"10.3389\/fmed.2024.1368093","volume":"11","author":"M Mendoza-\u00c1vila","year":"2024","unstructured":"Mendoza-\u00c1vila M, Esparza-P\u00e9rez H, Castillo-L\u00f3pez JA, Rodea-Montero ER. Agreement between PSMA-RADS and E-PSMA systems in classifying [18F]PSMA-1007 PET\/CT lesions among prostate cancer patients: exploring the correlation between lesion size and uptake. Front Med. 2024;11:1368093.","journal-title":"Front Med"},{"key":"2103_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40336-024-00631-6","volume":"12","author":"S Woo","year":"2024","unstructured":"Woo S, Freedman D, Becker AS, Leithner D, Mayerhoefer ME, Friedman KP, et al. Equivocal bone lesions on PSMA PET\/CT: systematic review and meta-analysis on their prevalence and malignancy rate. Clin Transl Imaging. 2024;12:485\u2013500.","journal-title":"Clin Transl Imaging"},{"key":"2103_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/pros.22742","volume":"74","author":"G Gandaglia","year":"2014","unstructured":"Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate. 2014;74:210\u20136.","journal-title":"Prostate"},{"key":"2103_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2967\/jnumed.118.217653","volume":"60","author":"Y Yin","year":"2019","unstructured":"Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, et al. Follow-up of lesions with equivocal radiotracer uptake on PSMA-targeted PET in patients with prostate cancer: predictive values of the PSMA-RADS-3A and PSMA-RADS-3B categories. J Nucl Med. 2019;60:511\u20136.","journal-title":"J Nucl Med"},{"key":"2103_CR23","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3390\/tomography8060220","volume":"8","author":"T Garg","year":"2022","unstructured":"Garg T, Werner RA, Chung HW, Khatri W, Pienta KJ, Pomper MG, et al. Association of true positivity with serum prostate-specific antigen levels and other clinical factors in indeterminate PSMA-RADS-3A lesions identified on 18F-DCFPyL PET\/CT scans. Tomography. 2022;8:2639\u201347.","journal-title":"Tomography"},{"key":"2103_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40644-018-0175-3","volume":"18","author":"Z Keidar","year":"2018","unstructured":"Keidar Z, Gill R, Goshen E, Israel O, Davidson T, Morgulis M, et al. 68Ga-PSMA PET\/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls. Cancer Imaging. 2018;18:39.","journal-title":"Cancer Imaging"},{"key":"2103_CR25","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s00259-020-04718-w","volume":"47","author":"J Miksch","year":"2020","unstructured":"Miksch J, Bottke D, Krohn T, Thamm R, Bartkowiak D, Solbach C, et al. Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET\/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2020;47:2339\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2103_CR26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2967\/jnumed.119.241174","volume":"61","author":"LW Chiu","year":"2020","unstructured":"Chiu LW, Lawhn-Heath C, Behr SC, Juarez R, Perez PM, Lobach I, et al. Factors predicting metastatic disease in 68Ga-PSMA-11 PET-positive osseous lesions in prostate cancer. J Nucl Med. 2020;61:1779\u201385.","journal-title":"J Nucl Med"},{"key":"2103_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/RLU.0000000000004259","volume":"47","author":"A Letang","year":"2022","unstructured":"Letang A, Cromb\u00e9 A, Rousseau C, Sargos P, Merlin C, Cantarel C, et al. Bone uptake in prostate cancer patients: diagnostic performances of PSMA-RADS v1.0, clinical, biological, and 68 Ga-PSMA-11 PET features to predict metastasis after biochemical recurrence. Clin Nucl Med. 2022;47:529\u201339.","journal-title":"Clin Nucl Med"},{"key":"2103_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13550-020-00745-8","volume":"11","author":"J Kuten","year":"2021","unstructured":"Kuten J, Dekalo S, Mintz I, Yossepowitch O, Mano R, Even-Sapir E. The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. EJNMMI Res. 2021;11:3.","journal-title":"EJNMMI Res"},{"key":"2103_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Sch\u00f6pfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578\u201383.","journal-title":"Hum Pathol"},{"key":"2103_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40644-018-0154-8","volume":"18","author":"J Damjanovic","year":"2018","unstructured":"Damjanovic J, Janssen JC, Furth C, Diederichs G, Walter T, Amthauer H, et al. 68 Ga-PSMA-PET\/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer. Cancer Imaging. 2018;18:20.","journal-title":"Cancer Imaging"},{"key":"2103_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2967\/jnumed.119.232504","volume":"61","author":"A Toriihara","year":"2020","unstructured":"Toriihara A, Nobashi T, Baratto L, Duan H, Moradi F, Park S, et al. Comparison of 3 interpretation criteria for 68Ga-PSMA11 PET based on inter- and intrareader agreement. J Nucl Med. 2020;61:533\u20139.","journal-title":"J Nucl Med"},{"key":"2103_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/RLU.0000000000005409","volume":"49","author":"Y Cui","year":"2024","unstructured":"Cui Y, Zhou X, Song Y, Zhai S, Li N. The value of PSMA-RADS version 2.0 in the assessment of pulmonary metastases in patients with prostate cancer and the improvement of differential diagnosis efficiency by PSMA PET\/CT parameters. Clin Nucl Med. 2024;49:566\u201373.","journal-title":"Clin Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02103-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:05:22Z","timestamp":1768165522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02103-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02103-x","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}